CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation

This study demonstrates that CA19-9 drives pancreatic cancer liver metastasis by mediating E-selectin-dependent tumor cell extravasation and promoting AKT-associated outgrowth, thereby establishing it as a functional driver and potential therapeutic target.

The Gist

The Big Picture: A Deadly "Sticky" Marker

Imagine pancreatic cancer as a group of rogue invaders trying to escape their home base (the pancreas) and take over a very important city (the liver). The liver is the most common place these invaders set up a new headquarters, and once they do, it's very hard to stop them.

For decades, doctors have used a specific "flag" called CA19-9 to track these invaders. If the flag is high in a patient's blood, it usually means the cancer is aggressive and likely to come back after surgery. But until now, scientists weren't sure if this flag was just a passive sign (like a smoke alarm going off because there's a fire) or if the flag itself was actively helping the fire spread.

This paper proves that the flag isn't just a warning sign; it's a tool the cancer uses to survive and spread.

---

The Story: How the Cancer Travels

1. The "Velcro" Problem (Getting to the Liver)

To get from the pancreas to the liver, cancer cells have to travel through the bloodstream. Think of the blood vessels as a fast-flowing river. To stop and settle in the liver, the cancer cells need to grab onto the riverbank (the blood vessel wall) and pull themselves out.

• The Discovery: The researchers found that cancer cells with the CA19-9 flag have special "Velcro" on their surface.
• The Dock: The riverbank (blood vessel wall) has a matching "hook" called E-selectin.
• The Result: When the cancer cell with the CA19-9 flag floats by, the Velcro snaps onto the hook. This stops the cell from being washed away and allows it to stick, squeeze through the wall, and enter the liver tissue. Without this Velcro, the cancer cells just float right past the liver.

2. The "Engine" Problem (Growing in the Liver)

Once the cancer cells successfully stick to the liver and get inside, they have to start building a new colony (metastasis).

• The Discovery: The CA19-9 flag doesn't just help them stick; it also acts like a turbocharger for the cancer cell's internal engine.
• The Mechanism: It turns on a specific pathway inside the cell called AKT. Think of AKT as the "growth and survival switch." When CA19-9 is present, this switch is stuck in the "ON" position.
• The Result: The cancer cells grow faster and are much harder to kill. They don't just survive; they thrive and multiply rapidly.

---

The Experiments: Proving the Theory

Since mice naturally don't have this CA19-9 flag (their "Velcro" doesn't work), the scientists had to be creative. They genetically engineered mouse cancer cells to wear the human CA19-9 flag.

1. The "Velcro" Test: They injected these cells into mice. The cells with the flag created massive tumors in the liver. The cells without the flag barely made any.
2. Cutting the Hook: They used mice that were genetically missing the "hook" (E-selectin) in their blood vessels. Even when they injected the cancer with the flag, the cancer couldn't stick or spread. This proved the Velcro-and-hook connection is essential.
3. The "Anti-Velcro" Weapon: They tried using a special antibody (a type of medicine) that covers up the CA19-9 flag.
   • The Magic: When they gave this medicine to the mice, the cancer cells lost their "Velcro." They couldn't stick to the liver, and if they were already there, they stopped growing and started dying.

---

Why This Matters: A New Way to Fight Cancer

This study changes how we view CA19-9. It's not just a number on a lab report; it's a weapon the cancer uses.

• The Old Way: We thought CA19-9 just told us how bad the cancer was.
• The New Way: We now know CA19-9 is making the cancer worse by helping it stick to the liver and grow.

The Good News: Because we know exactly how this works (the Velcro hook and the turbo engine), we can design drugs to break it.

• We can use antibodies to cover the CA19-9 flag so the cancer can't stick.
• We can block the "hook" on the blood vessels.
• We can turn off the "turbo engine" (AKT pathway) inside the cancer cells.

The Bottom Line

This research suggests that targeting the CA19-9 flag could be a powerful new strategy to stop pancreatic cancer from spreading to the liver. It's like realizing the invaders aren't just carrying a flag; they are using that flag as a grappling hook to climb the walls and a remote control to turn on their growth engines. If we can cut the hook and jam the remote, we might finally be able to stop them in their tracks.

Technical Summary

1. Problem Statement

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a 5-year survival rate of only 13%, primarily due to early metastasis, most commonly to the liver. CA19-9 (sialyl Lewis a) is the standard clinical biomarker for PDAC; elevated serum levels correlate with poor prognosis and early recurrence. However, it remains unclear whether CA19-9 is merely a passive marker of tumor burden or a functional driver of metastatic progression.

• Key Limitation: Previous research into the biological role of CA19-9 in vivo has been hindered because mice lack the FUT3 gene (a pseudogene in rodents), meaning they do not naturally produce CA19-9. This gap has prevented the validation of CA19-9 as a therapeutic target in animal models.

2. Methodology

The authors utilized a combination of genetically engineered mouse models, in vitro assays, and human tissue analysis to dissect the role of CA19-9.

• Model Generation:
  • Created syngeneic murine PDAC cell lines (FC1199, FC1245, KPCY) derived from Kras; Trp53; Pdx1-Cre (KPC) mice.
  • Engineered these cells to express human FUT3 and B3GALT5, enabling the production of CA19-9 (CA19-9^pos), compared to control cells lacking these enzymes (CA19-9^neg).
  • Generated E-selectin knockout (Sele^-/-) mice and used NSG (immunocompromised) mice to assess immune-independent mechanisms.
• In Vivo Metastasis Models:
  • Hemisplenic Injection: Tumor cells were injected into the spleen to facilitate direct portal circulation entry into the liver, followed by splenectomy. This models the seeding and outgrowth of liver metastases.
  • Therapeutic Intervention: Mice were treated with neutralizing antibodies against CA19-9 (clone 5B1) or E-selectin (clone 9A9) either pre- or post-seeding to distinguish effects on seeding vs. outgrowth.
• In Vitro Assays:
  • Adhesion Assays: Co-culture of PDAC cells with TNF-α-stimulated HUVECs (to induce E-selectin) to measure vascular adhesion.
  • Blocking Experiments: Used anti-CA19-9 and anti-E-selectin antibodies, as well as CRISPR/Cas9-mediated FUT3 knockout in human Capan-2 cells.
• Molecular & Clinical Analysis:
  • RNA-seq & Western Blot: To identify signaling pathways (PI3K-AKT-mTOR) activated by CA19-9.
  • Tissue Microarray (TMA): Immunofluorescence staining of human PDAC tissues to correlate CA19-9 expression with pAKT levels and patient survival (focusing on early-stage T1N0M0 patients to control for tumor burden).

3. Key Contributions

• Overcoming the Mouse Model Gap: Successfully established the first syngeneic murine PDAC models expressing CA19-9, allowing for the first in vivo functional assessment of this glycan in metastasis.
• Mechanistic Decoupling: Demonstrated that CA19-9 drives metastasis through two distinct mechanisms:
  1. Seeding: Via E-selectin-mediated adhesion and extravasation.
  2. Outgrowth: Via intracellular AKT signaling activation.
• Therapeutic Validation: Provided preclinical evidence that targeting CA19-9 (via antibody 5B1) is effective at both preventing seeding and inhibiting the outgrowth of established metastases, whereas E-selectin blockade primarily affects seeding.

4. Key Results

A. CA19-9 Promotes Liver Metastasis

• Seeding and Outgrowth: In splenic injection models, CA19-9^pos cells resulted in significantly higher liver metastatic burden (increased liver weight, tumor area, and number/size of foci) compared to CA19-9^neg cells.
• Dual Effect: The increase in metastatic burden was driven by both an increased number of initial metastatic foci (seeding) and larger tumor size (outgrowth).
• Proliferation/Apoptosis: While CA19-9^pos tumors were larger, Ki67 (proliferation) and Cleaved Caspase-3 (apoptosis) levels were not significantly different at the endpoint, suggesting CA19-9 enhances survival/colonization rather than just raw proliferation rates.

B. E-Selectin Mediates Seeding (Extravasation)

• Adhesion: CA19-9^pos cells showed robust adhesion to TNF-α-stimulated HUVECs. This adhesion was abolished by blocking CA19-9, blocking E-selectin, or knocking out FUT3.
• In Vivo Seeding:
  • E-selectin KO Mice: Mice lacking E-selectin showed a drastic reduction in liver metastatic seeding (fewer YFP⁺ cells at Day 1) and overall metastatic burden compared to Wild-Type mice.
  • Antibody Neutralization: Pre-treatment with anti-CA19-9 or anti-E-selectin antibodies significantly reduced the number of metastatic foci formed 24 hours post-injection.
• Conclusion: The CA19-9/E-selectin axis is critical for the extravasation and initial seeding of tumor cells in the liver.

C. CA19-9 Drives Outgrowth via AKT Signaling

• Signaling Pathway: RNA-seq and Western blotting revealed that CA19-9 expression activates the PI3K-AKT-mTOR pathway (increased pAKT and pS6) but not MAPK/ERK.
• Therapeutic Timing:
  • Anti-CA19-9 Antibody: When administered after seeding (Day 3), it significantly reduced liver metastatic burden and increased apoptosis, indicating it inhibits outgrowth.
  • Anti-E-selectin Antibody: When administered after seeding, it had no effect on established metastatic outgrowth.
• Mechanism: CA19-9 blockade reduced pAKT levels in tumors, linking the glycan directly to AKT-driven survival and colonization.

D. Clinical Correlation

• Human Tissue: In human PDAC tissue microarrays, there was a significant positive correlation between CA19-9 expression and pAKT levels.
• Prognosis: Even in early-stage (Stage IA, T1N0M0) patients where tumor size is small, high preoperative CA19-9 levels were associated with significantly worse Disease-Free Survival (DFS) and Overall Survival (OS), supporting the idea that CA19-9 reflects aggressive biological properties (metastatic potential) independent of tumor volume.
• Immune Context: The enhanced metastasis was observed in immunocompromised (NSG) mice, and immune cell infiltration (CD8⁺, Tregs, Macrophages) was unchanged in WT mice, suggesting the mechanism is not primarily driven by immune evasion.

5. Significance

• Paradigm Shift: This study redefines CA19-9 from a passive diagnostic biomarker to an active functional driver of PDAC metastasis.
• Therapeutic Implications:
  • Dual-Stage Targeting: Targeting CA19-9 (e.g., with the humanized antibody 5B1) offers a unique therapeutic window, potentially effective in both the adjuvant setting (preventing seeding/recurrence) and metastatic settings (inhibiting outgrowth of established disease).
  • Differentiation from E-selectin: While E-selectin inhibitors may be useful for preventing initial seeding, they may not be sufficient for treating established metastases, whereas CA19-9 targeting addresses both.
• Clinical Relevance: The findings provide a mechanistic rationale for the strong clinical association between CA19-9 levels and poor outcomes, suggesting that monitoring CA19-9 reflects the activation of pro-metastatic AKT signaling.
• Future Directions: Supports the advancement of CA19-9-targeted therapies (like BNT321) in clinical trials, particularly in post-resection adjuvant settings where tumor burden is low and circulating antigen levels are manageable.